Efficacy and safety comparison of everolimus and fulvestrant in patients with estrogen receptor-positive advanced breast cancer progressed after endocrine therapy
10.3969/j.issn.1006-5725.2018.10.001
- VernacularTitle:依维莫司和氟维司群在内分泌耐药晚期乳腺癌中的疗效对比
- Author:
Yingfei DENG
1
;
Cong XUE
;
Xin AN
;
Wei YANG
;
Yanxia SHI
;
Ye CAO
Author Information
1. 中山大学肿瘤防治中心 广州 510030
- Keywords:
fulvestrant;
everolimus;
advanced breast cancer;
endocrine resistance
- From:
The Journal of Practical Medicine
2018;34(10):1581-1584
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of everolimus combined with endocrine therapy and fulvestrant in patients with estrogen receptor-positive advanced breast cancer progressed after endocrine thera-py. Methods Ninety-three breast cancer patients were selected from January 2014 to February 2017. The primary end points were progression-free survival and clinical benefit rate and the secondary end points was tolerability. Re-sults The progression-free survival in fulvestrant group was slightly higher than that in the everolimus group(13.4 months vs 12.2 months,P = 0.297). The clinical benefit rates were 46.15% and 31.71% in fulvestrant group and everolimus group,respectively. Patients treated with fewer than 2 lines and endocrine resistant patients benefited more from fulvestrant but without statistical difference. The main adverse events related to everolimus were stomati-tis,with a prevalence rate of about 26% and a localized pneumonia with a prevalence rate of about 10%. The main adverse reaction of fulvestrant was the injection site reaction. Conclusions The efficacy of everolimus in combina-tion with endocrine therapy is not superior to that of fulvestrant for the treatment of advanced breast cancer pro-gressed after endocrine therapy. After weighing the clinical benefits and quality of life,fulvestrant may be better for patients treated with fewer than 2 lines and endocrine resistance.
